WO2005085195A1 - 神経障害に伴う過活動膀胱の予防または治療用医薬組成物 - Google Patents
神経障害に伴う過活動膀胱の予防または治療用医薬組成物 Download PDFInfo
- Publication number
- WO2005085195A1 WO2005085195A1 PCT/JP2005/002913 JP2005002913W WO2005085195A1 WO 2005085195 A1 WO2005085195 A1 WO 2005085195A1 JP 2005002913 W JP2005002913 W JP 2005002913W WO 2005085195 A1 WO2005085195 A1 WO 2005085195A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- overactive bladder
- neuropathy
- drugs
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
Definitions
- the present invention relates to a pharmaceutical composition useful for preventing or treating overactive bladder associated with neuropathy.
- the present invention provides a compound represented by the general formula
- R in the formula may have a hydroxyl group, a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, a cycloalkyl group, an aryl group or one or more halogen atoms as a substituent, and may have an unsaturated bond.
- It may have an aliphatic acyl group, a hydroxy lower alkyl group, an aliphatic acyloxy alkyl group, a lower alkoxy group as a substituent, a phenol group, a lower alkoxy carbonyl group, an aryl substituted lower alkoxy carbonyl group, a rubamoyl group
- a lower alkyl group having a mono- or di-lower alkyl-substituting ability such as a rubamoyl group or a cyano group, an aromatic acyl group optionally having one or more halogen atoms as a substituent, a furoyl group or a pyridylcarbonyl group.
- R 1 is Xia amino group or force Rubamoiru group
- R 2 is a substituent Or an indoline derivative represented by the formula (I) or an alkyl group which may have one or more halogen atoms) or a pharmacologically acceptable salt thereof.
- the present invention relates to a pharmaceutical composition for preventing or treating overactive bladder associated with neuropathy. Background art
- Overactive bladder is a disease defined based on symptoms of urinary urgency and frequent urination, usually with or without urge incontinence. This is a definition proposed in a new terminology standard reported by the International Contraindicated Society (ICS) (see Non-Patent Document 1), From epidemiological surveys conducted as a research project of the academic society, it is estimated that more than 8 million overactive bladder patients are presently present (see Non-Patent Document 2).
- overactive bladder In addition to essential overactive bladder whose cause is not clear, overactive bladder often appears due to neuropathy, lower urinary tract obstruction disease and the like, and there are various treatment methods depending on its causes (Non-patent Documents) 3). In overactive bladder due to neuropathy, nervous lesions caused by cerebrovascular disorders, Parkinson's disease, and spinal cord injury cause abnormal urination control and impaired perception, resulting in overactive bladder. Therefore, various treatments have been attempted for urinary urgency and frequent urination in overactive bladder, but in many cases, sufficient effects are not always obtained. It is hoped that new treatment methods will be established.
- the compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has a selective inhibitory action on urethral smooth muscle contraction, and suppresses intraurethral pressure without significantly affecting blood pressure. It has been reported that the compound is extremely useful as a therapeutic agent for reducing urinary disorders associated with benign prostatic hyperplasia (see Patent Document 1). However, there is no description or suggestion that the compound represented by the general formula (I) is useful for preventing or treating overactive bladder associated with neuropathy.
- Patent Document 1 JP-A-6-220015
- Non-Patent Document 1 Y. Homma et al., “Terminology for Lower Urinary Tract Function: Report of the International Standardization Committee of the Continuing Society”, Journal of the Japan Association of Urinary Function, 2003, Vol. 14, No. 2, p. 278- 289
- Non-Patent Document 2 Y.Honma et al., "Epidemiological Study on Urination", Journal of the Japan Association of Urinary Function, 2003, Vol. 14, No. 2, p. 266-277
- Non-Patent Document 3 Osamu Yamaguchi, “Mechanism of Overactive Bladder”, PHARMACIA SCOPE, Fanore Macia Co., Ltd., 2003, Vol. 42, No. 4, p. 12-13
- Non Patent Literature 4 Osamu Nishizawa, "What is Overactive Bladder (OAB)?", PHARMACIA SCOPE, Fanoremasia Co., Ltd., 2003, Vol. 42, No. 1, p. 14-15
- An object of the present invention is to provide a pharmaceutical composition useful for preventing or treating overactive bladder associated with neuropathy.
- the present inventors have conducted intensive studies to find a compound useful for the prevention or treatment of overactive bladder associated with neuropathy. As a result, the compound represented by the general formula (I) was The present inventors have found that the frequency of occurrence of involuntary contractions is remarkably suppressed, and that the present invention has an effect of prolonging the interval between urinations.
- the present invention provides:
- R in the formula may have a hydroxyl group, a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, a cycloalkyl group, an aryl group or one or more halogen atoms as a substituent, and may have an unsaturated bond.
- acyl group which may have an aliphatic acyl group, a hydroxy lower alkyl group, an aliphatic acyloxy alkyl group, a lower alkoxy group as a substituent, a carboxy group, a lower alkoxy carbonyl group, an aryl substituted lower alkoxy carbonyl group, a carbamoyl group
- a lower alkyl group having a mono- or di-lower alkyl-substituting ability such as a rubamoyl group or a cyano group, an aromatic acyl group optionally having one or more halogen atoms as a substituent, a furoyl group or a pyridylcarbonyl group.
- R 1 is Xia amino group or force Rubamoiru group
- R 2 is a substituent Shiano group, Ariru group or one Or a lower alkyl group which may have a halogen atom or more), or a pharmacologically acceptable salt thereof as an active ingredient.
- the active ingredient is (_) _ 1_ (3-hydroxypropyl) _5 _ ((2R) _2 ⁇ ⁇ [2 _ ( ⁇ 2 _ [(2,2,2-tritrifluoroethyl) oxy] phenyl] oxy) ethyl ] Amino ⁇ propyl) -2,3-dihydro-1H-indole-7-carboxamide or a pharmacologically acceptable salt thereof; the pharmaceutical composition according to the above (1);
- neuropathy is cerebrovascular disorder, Parkinson's disease, spinal cord disorder, peripheral neuropathy or multiple sclerosis;
- Drugs whose other drugs used for overactive bladder due to neuropathy are selected from anticholinergics, anxiolytics, cholinergic drugs, cholinesterase inhibitors, antispasmodics, anti-inflammatory drugs, and antibacterial drugs.
- overactive bladder associated with neuropathy refers to overactive bladder defined by the above-mentioned new term standard of ICS, which is caused by neuropathy.
- the neuropathy include cerebrovascular disorders such as cerebral infarction or cerebral hemorrhage, spinal cord disorders such as Parkinson's disease and spinal cord injury, peripheral neuropathy associated with diabetes and the like, and multiple sclerosis.
- Overactive bladder associated with neuropathy includes neuropathic bladder (e.g., due to cerebrovascular disorder, spinal cord disorder, diabetic neuropathy, multiple sclerosis, etc.) and unstable bladder, but prostate enlargement It does not include those caused by lower urinary tract obstruction diseases such as infectious diseases.
- the present inventors have shown in a pharmacological test using a spinal cord-injured rat that the compound represented by the general formula (I) has an inhibitory effect on the involuntary contraction frequency during urine collection and a prolonged effect on the urination interval.
- These results support the usefulness of the compound for urinary urgency and frequent urination in overactive bladder associated with neuropathy.
- the compound represented by the general formula (I) shows that It was shown to be extremely useful in preventing or treating active bladder.
- lower alkyl means methyl, ethyl, A straight-chain or branched alkyl having 16 carbon atoms such as pill, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, etc. Linear and branched alkoxy are referred to, and cycloalkyl is a 5- to 7-membered cyclic alkyl.
- arylene refers to aromatic hydrocarbon groups such as phenyl and naphthyl
- aromatic acyl refers to the carboxylic acid acyl having the above aryl
- aliphatic acyl that may have an unsaturated bond refers to carbon atoms having 2 carbon atoms.
- a straight-chain and branched alkyl carboxylic acid consisting of 7 or a straight-chain or branched alkenyl carboxylic acid consisting of 3 to 7 carbon atoms is referred to as an aliphatic acyloxyalkyl.
- the above-mentioned lower alkyl having a hydroxyl group substituted by the above-mentioned aliphatic acryl group is the same.
- furoyl is 2-furoyl and 3-furoyl
- pyridylcarbonyl is 2_pyridylcarbonyl
- halogen is fluorine, chlorine and bromine.
- iodine atoms respectively.
- preferred compounds include, for example, (1) _1_ (3-hydroxypropyl) -15-((2R) -2-[[2 _ ( ⁇ 2_ [ (2,2,2_Trifluoroethyl) oxy] phenyl ⁇ oxy) ethyl] amino ⁇ propyl) -1,2,3-dihydro-1H-indolinone 7_carboxamide and its pharmacologically acceptable salts (Of these, dihydrobromide is hereinafter referred to as compound 1).
- Examples of the pharmacologically acceptable salt of the compound represented by the general formula (I) include salts with inorganic bases such as sodium, potassium, calcium and the like, morpholine, piperidine and the like.
- the compounds represented by the general formula (I) include pharmaceutically acceptable products such as hydrates and ethanol. And solvates with the solvent used.
- the compound of the present invention includes a single crystal polymorph, a mixture of two or more crystal polymorphs, and a mixture thereof with an amorphous substance, regardless of an amorphous substance or a crystal substance.
- the compound represented by the above general formula (I) has at least one asymmetric carbon, and has two (R) and (S) configurations at each asymmetric carbon.
- compounds of any configuration may be used, and mixtures thereof are also included.
- those having an unsaturated bond include geometric isomers of E and Z.
- any of the compounds is used.
- the compound represented by the general formula (I) may be used in combination with one or more other drugs used for overactive bladder accompanying neuropathy.
- Other drugs that can be used in combination include, for example, anticholinergics (tolterodine, oxyptinin, propiverine, etc.), anxiolytics, cholinergic drugs (bethanechol chloride, etc.), cholinesterase inhibitors (distigmine bromide, etc.), antispasmodics Drugs (flavoxate, etc.), anti-inflammatory drugs, antibacterial drugs, etc. can be mentioned.
- the present invention relates to simultaneous administration as a single preparation and separate preparations
- the above-mentioned compound of the present invention and the above-mentioned other drugs are included in any of the above-mentioned administration forms, that is, simultaneous administration by the same or different administration routes, and administration at different intervals by the same or different administration routes as separate preparations.
- the pharmaceutical composition used in combination includes a dosage form as a single preparation as described above and a dosage form in which separate preparations are combined.
- the compound represented by the general formula (I) can be used in an appropriate combination with one or more other drugs described above to provide an additive effect in preventing or treating the above diseases.
- the advantageous effect of can be obtained.
- the use amount can be reduced as compared with the case of using alone, or the side effect of the above-mentioned drug used in combination can be avoided or reduced.
- dosage forms are used depending on the usage.
- dosage forms include, for example, powders, granules, fine granules, and dry syrups. Tablets, capsules, injections, solutions, ointments, suppositories, patches and the like, and are administered orally or parenterally.
- compositions can be prepared by using a suitable excipient, disintegrant, binder, lubricant, diluent, buffer, isotonic agent, etc. according to the method used in pharmacy depending on the dosage form. It can be produced by mixing or diluting and dissolving with pharmaceutical additives such as preservatives, wetting agents, emulsifiers, dispersing agents, stabilizers, and solubilizing agents, and dispensing according to a conventional method. When other drugs are used in combination, they can be manufactured by simultaneously or separately formulating the respective active ingredients in the same manner as described above.
- a powder is prepared by adding an appropriate excipient, lubricant and the like to the compound represented by the above general formula (I) as needed and mixing well.
- tablets are prepared by adding a suitable excipient, disintegrant, binder, lubricant and the like to the compound represented by the above general formula (I), if necessary, and compressing the mixture according to a conventional method. Tablets.
- the tablets can be coated, if necessary, to give film-coated tablets, sugar-coated tablets, enteric-coated tablets and the like.
- a capsule is prepared by adding a suitable excipient, a lubricant and the like to a compound represented by the above general formula (I) if necessary, and then filling the mixture into an appropriate capsule. Make capsules. Further, after the granules or fine granules are formed by an ordinary method, they may be filled.
- the dose of the compound represented by the general formula (I), which is an active ingredient thereof depends on the weight, age, sex, disease, and treatment of the patient.
- oral administration is generally in the range of 0.5 to 500 mg / day for adults
- parenteral administration is in the range of 0.05 to 100 mg / day for adults once or several times a day. It can be divided and administered as appropriate.
- the dose of the compound of the present invention can be reduced according to the dose of the other drug.
- the pharmaceutical composition of the present invention exhibits an excellent improving effect on the frequency of involuntary contractions and urination interval as indicators of urgency and urinary frequency in overactive bladder due to neuropathy such as spinal cord injury.
- a physician useful for the prevention or treatment of overactive bladder associated with neurological disorders according to the present invention A drug composition can be provided.
- FIG. 1 shows the effect of a rat spinal cord injury overactive bladder model on urination interval.
- the mouth indicates the data before administration, and the country indicates the data of compound 1.
- the vertical axis shows the urination interval relative to the value before drug administration in percentage.
- FIG. 2 shows the effect of the rat spinal cord injury overactive bladder model on the frequency of involuntary contractions occurring during urine collection.
- the mouth indicates the data before administration, and the country indicates the data of compound 1.
- the vertical axis indicates the frequency of occurrence of involuntary contraction relative to the value before drug administration, as a percentage.
- the spinal cord of a female rat under ether anesthesia was cut at the ThlO site and spinal injury was performed.
- the rats were anesthetized with pentobarbital, and a catheter filled with a saline solution was inserted into the bladder, ligated, pulled out from the back of the neck, and stoppered.
- a catheter filled with heparinka saline was inserted into the jugular vein, ligated, pulled out from the back of the neck, and plugged.
- cystometry was performed on rats that were not awake.
- Physiological saline was infused into the bladder at a flow rate of 12 mL / hr.
- Drugs were administered from a jugular vein catheter derived from the back of the neck. As a result, involuntary contraction was observed during urine collection in the female rat spinal cord model. Intravenous administration of Compound 1 (0.1 mg / kg) prolonged the voiding interval in the same model by about 20% (Figure 1) and reduced the frequency of involuntary contractions that occurred during urination by about 20% ( Figure 2). .
- the compound represented by the general formula (I) has an effect on the frequency of involuntary contractions and urination interval as indicators of urgency and frequent urination. It showed an excellent ameliorating effect and was extremely useful for preventing or treating overactive bladder associated with neuropathy.
- the pharmaceutical composition of the present invention exhibits excellent urinary urgency and frequent urination, and It is extremely useful as an agent for preventing or treating overactive bladder due to a disorder.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2557758A CA2557758C (en) | 2004-03-05 | 2005-02-23 | Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder |
EP05719421.9A EP1724257B1 (en) | 2004-03-05 | 2005-02-23 | Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder |
ES05719421.9T ES2436608T3 (es) | 2004-03-05 | 2005-02-23 | Composición medicinal para la prevención o el tratamiento de la vejiga hiperactiva asociada a un trastorno nervioso |
JP2006510642A JP5004215B2 (ja) | 2004-03-05 | 2005-02-23 | 神経障害に伴う過活動膀胱の予防または治療用医薬組成物 |
US10/598,533 US20070167511A1 (en) | 2004-03-05 | 2005-02-23 | Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder |
CN2005800071364A CN1930123B (zh) | 2004-03-05 | 2005-02-23 | 用于预防或治疗伴有神经障碍的膀胱过度活动症的医药组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-061476 | 2004-03-05 | ||
JP2004061476 | 2004-03-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005085195A1 true WO2005085195A1 (ja) | 2005-09-15 |
Family
ID=34918068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/002913 WO2005085195A1 (ja) | 2004-03-05 | 2005-02-23 | 神経障害に伴う過活動膀胱の予防または治療用医薬組成物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20070167511A1 (ja) |
EP (1) | EP1724257B1 (ja) |
JP (1) | JP5004215B2 (ja) |
KR (1) | KR20070003968A (ja) |
CN (1) | CN1930123B (ja) |
CA (1) | CA2557758C (ja) |
ES (1) | ES2436608T3 (ja) |
TW (1) | TWI369984B (ja) |
WO (1) | WO2005085195A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1800677A1 (en) * | 2004-10-05 | 2007-06-27 | Kissei Pharmaceutical Co., Ltd. | Preventive and/or therapeutic agent for urine collection disorder accompanying lower urinary tract obstruction |
EP1806136A1 (en) * | 2004-10-06 | 2007-07-11 | Kissei Pharmaceutical Co., Ltd. | Medicinal composition for prevention of transition to operative treatment for prostatic hypertrophy |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005092321A1 (ja) * | 2004-03-24 | 2005-10-06 | Kissei Pharmaceutical Co., Ltd. | 頻尿または尿失禁の予防または治療用医薬組成物 |
US20080242717A1 (en) * | 2007-02-28 | 2008-10-02 | Fumiyasu Sato | Methods for treating benign prostatic hyperplasia |
JP4497192B2 (ja) | 2007-11-08 | 2010-07-07 | 船井電機株式会社 | 光ディスク装置 |
RU2585727C1 (ru) * | 2014-12-12 | 2016-06-10 | Наталья Борисовна Гусева | Способ лечения детей с гиперактивным мочевым пузырем |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1432007A (en) | 1920-07-09 | 1922-10-17 | Ajax Metal Company | Tilting mechanism for furnaces and the like |
JPH06220015A (ja) | 1992-12-02 | 1994-08-09 | Kissei Pharmaceut Co Ltd | インドリン誘導体 |
WO1999015202A1 (fr) | 1997-09-22 | 1999-04-01 | Kissei Pharmaceutical Co., Ltd. | Medicaments contre la dysurie resultant d'une hypertrophie de la prostate |
WO1999048530A1 (en) | 1998-03-23 | 1999-09-30 | Merck & Co., Inc. | Combination therapy for the treatment of benign prostatic hyperplasia |
JP2000247998A (ja) | 1999-02-26 | 2000-09-12 | Kissei Pharmaceut Co Ltd | α1Aアドレナリン受容体の変異体、当該変異体を用いた測定方法及び前立腺肥大に伴う排尿困難症治療剤 |
JP2001288115A (ja) | 2001-02-07 | 2001-10-16 | Yamanouchi Pharmaceut Co Ltd | 下部尿路症治療剤 |
US20020143007A1 (en) * | 1996-02-02 | 2002-10-03 | Garvey David S. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use |
WO2004022538A1 (ja) | 2002-09-06 | 2004-03-18 | Kissei Pharmaceutical Co., Ltd. | 経口用固形医薬用結晶およびそれを含む排尿障害治療用経口用固形医薬 |
WO2004054574A1 (ja) | 2002-12-16 | 2004-07-01 | Kissei Pharmaceutical Co., Ltd. | 経口固形医薬 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994294A (en) * | 1996-02-02 | 1999-11-30 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
US5932538A (en) * | 1996-02-02 | 1999-08-03 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
US6294517B1 (en) * | 1996-02-02 | 2001-09-25 | Nitromed, Inc. | Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use |
US6410554B1 (en) * | 1998-03-23 | 2002-06-25 | Merck & Co., Inc. | Combination therapy for the treatment of benign prostatic hyperplasia |
-
2005
- 2005-02-23 WO PCT/JP2005/002913 patent/WO2005085195A1/ja active Application Filing
- 2005-02-23 US US10/598,533 patent/US20070167511A1/en not_active Abandoned
- 2005-02-23 JP JP2006510642A patent/JP5004215B2/ja not_active Expired - Fee Related
- 2005-02-23 EP EP05719421.9A patent/EP1724257B1/en not_active Not-in-force
- 2005-02-23 ES ES05719421.9T patent/ES2436608T3/es active Active
- 2005-02-23 KR KR1020067019606A patent/KR20070003968A/ko active Search and Examination
- 2005-02-23 CN CN2005800071364A patent/CN1930123B/zh not_active Expired - Fee Related
- 2005-02-23 CA CA2557758A patent/CA2557758C/en not_active Expired - Fee Related
- 2005-03-04 TW TW094106579A patent/TWI369984B/zh not_active IP Right Cessation
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1432007A (en) | 1920-07-09 | 1922-10-17 | Ajax Metal Company | Tilting mechanism for furnaces and the like |
JPH06220015A (ja) | 1992-12-02 | 1994-08-09 | Kissei Pharmaceut Co Ltd | インドリン誘導体 |
US20020143007A1 (en) * | 1996-02-02 | 2002-10-03 | Garvey David S. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use |
WO1999015202A1 (fr) | 1997-09-22 | 1999-04-01 | Kissei Pharmaceutical Co., Ltd. | Medicaments contre la dysurie resultant d'une hypertrophie de la prostate |
WO1999048530A1 (en) | 1998-03-23 | 1999-09-30 | Merck & Co., Inc. | Combination therapy for the treatment of benign prostatic hyperplasia |
JP2000247998A (ja) | 1999-02-26 | 2000-09-12 | Kissei Pharmaceut Co Ltd | α1Aアドレナリン受容体の変異体、当該変異体を用いた測定方法及び前立腺肥大に伴う排尿困難症治療剤 |
JP2001288115A (ja) | 2001-02-07 | 2001-10-16 | Yamanouchi Pharmaceut Co Ltd | 下部尿路症治療剤 |
WO2004022538A1 (ja) | 2002-09-06 | 2004-03-18 | Kissei Pharmaceutical Co., Ltd. | 経口用固形医薬用結晶およびそれを含む排尿障害治療用経口用固形医薬 |
WO2004054574A1 (ja) | 2002-12-16 | 2004-07-01 | Kissei Pharmaceutical Co., Ltd. | 経口固形医薬 |
Non-Patent Citations (19)
Title |
---|
AKIYAMA K. ET AL., JAPANESE JOURNAL OF PHARMACOLOGY, vol. 90, no. 2, 2002, pages 131 - 137 |
AKIYAMA K. ET AL: "Effects of KMD-3213, a uroselective <SYM97>1-adrenoceptor antagonist of the tilt-induced blood pressure response in Pharmacology.", JAPANESE JOURNAL OF PHARMACOLOGY., vol. 90, no. 2, 2002, pages 131 - 137, XP002992442 * |
ISHIDURA O. ET AL., GERIATRIC MEDICINE, vol. 41, no. 8, 2003, pages 1149 - 1153 |
ISHIDURA O. ET AL: "Koreisha no Zenritsusen Shikkan Zenritsusen Shikkan to Kakatsudo Boko.", GERIATR.MED., vol. 41, no. 8, 2003, pages 1149 - 1153, XP002992447 * |
ISHIZUKA O. ET AL., BR.J. PHARMACOL., vol. 117, no. 5, 1996, pages 962 - 966 |
ISHIZUKA O. ET AL: "Micturition in concious rats with and without bladder outlet obstruction: role of spinal alpha-adrenoceptors.", BR.J. PHARMACOL., vol. 117, no. 5, 1996, pages 962 - 966, XP002992446 * |
OHASHI T. ET AL: "Hainyo Shogai to Nyo Shikkin (Ge).", HEKKAN HONDANREN., no. 591, 1998, pages 57 - 60, XP002992445 * |
OKASHI T. ET AL.: "Urination Disorders and Incontinence", 1998, pages: 57 - 60 |
OKURA T. ET AL., JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 54, no. 7, 2002, pages 975 - 998 |
OKURA T. ET AL: "Selective and sustained occupancyof prostatic <SYM97>1Aadrenoceptor antagonist by oral administration of KMD-3213 and its plasma concentration in rats.", JOURNAL OF PHARMACY AND PHARMACOLOGY., vol. 54, no. 7, 2002, pages 975 - 998, XP002992444 * |
OSAMU NISHIMURA: "PHARMACIA SCOPE", vol. 42, 2003, PHARMACIA COMPANY, article "What is overactive bladder (OAB)?", pages: 14 - 15 |
OSAMU YAMAGUCHI: "PHARMACIA SCOPE", vol. 42, 2003, PHARMACIA COMPANY, article "Mechanism of overactive bladder", pages: 12 - 13 |
R.A. APPELL, REVIEWS IN UROLOGY, vol. 5, no. 8, 2003, pages 537 - 541 |
YAMADA S. ET AL., LIFE SCIENCE, vol. 62, no. 17-18, 1998, pages 1585 - 1589 |
YAMADA S. ET AL: "In vivo receptor binding of novel <SYM97>1-adrenoceptor antagonist for treatment of benign prostatic hyperplasia.", LIFE SCIENCE., vol. 62, no. 17-18, 1998, pages 1585 - 1589, XP002992441 * |
YOSHIDA M. ET AL., FOLIA PHARMACOLOGICA JAPONICA, vol. 121, no. 5, 2003, pages 307 - 316 |
YOSHIDA M. ET AL: "Kabu Nyoro Kino Kenkyu no Saikin no Shinpo: Kiso Kenkyu o Rinsho Oyo ni Tsugu 3 Kabu Nyoro Heikatsukin Kino ni Kakawaru Shinkei Dentatsu Busshitsu no Yakurigakuteki Bunseki.", FOLIA PHARMACOLOGICA JAPONICA., vol. 121, no. 5, 2003, pages 307 - 316, XP002992443 * |
YUKIO HONMA: "Epidemiologic survey on urination", JOURNAL OF NEUROGENIC BLADDER SOCIETY, vol. 14, no. 2, 2003, pages 266 - 277 |
YUKIO HONMA: "The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the international continence society", JOURNAL OF NEUROGENIC BLADDER SOCIETY, vol. 14, no. 2, 2003, pages 278 - 289 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1800677A1 (en) * | 2004-10-05 | 2007-06-27 | Kissei Pharmaceutical Co., Ltd. | Preventive and/or therapeutic agent for urine collection disorder accompanying lower urinary tract obstruction |
EP1800677A4 (en) * | 2004-10-05 | 2008-04-02 | Kissei Pharmaceutical | AGENT FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF URINE COLLECTION DISORDERS IN BLADDER OF THE BLADDER OF THE LOWER URINARY CANAL |
EP1806136A1 (en) * | 2004-10-06 | 2007-07-11 | Kissei Pharmaceutical Co., Ltd. | Medicinal composition for prevention of transition to operative treatment for prostatic hypertrophy |
EP1806136A4 (en) * | 2004-10-06 | 2008-03-12 | Kissei Pharmaceutical | THERAPEUTIC PREPARATION TO ELIMINATE THE TRANSITIONAL STEP TOWARDS THE OPERATIVE TREATMENT OF PROSTATIC HYPERTROPHY |
Also Published As
Publication number | Publication date |
---|---|
EP1724257B1 (en) | 2013-11-13 |
US20070167511A1 (en) | 2007-07-19 |
CA2557758C (en) | 2013-09-10 |
ES2436608T3 (es) | 2014-01-03 |
JPWO2005085195A1 (ja) | 2007-12-13 |
TWI369984B (en) | 2012-08-11 |
JP5004215B2 (ja) | 2012-08-22 |
EP1724257A4 (en) | 2009-10-28 |
CN1930123B (zh) | 2010-06-23 |
KR20070003968A (ko) | 2007-01-05 |
CA2557758A1 (en) | 2005-09-15 |
EP1724257A1 (en) | 2006-11-22 |
CN1930123A (zh) | 2007-03-14 |
TW200533344A (en) | 2005-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5263170B2 (ja) | 過活動膀胱治療用医薬組成物 | |
MXPA05004925A (es) | Remedio para vejiga hiperactiva que incluye derivado de anilida de acido acetico como el ingrediente activo. | |
ZA200603181B (en) | 3-(4-aminophenyl) thienopyrimid-4-one derivatives as MCH R1 antagonists for the treatment of obesity, diabetes, depression and anxiety | |
WO2005085195A1 (ja) | 神経障害に伴う過活動膀胱の予防または治療用医薬組成物 | |
WO2006016689A1 (ja) | Ep4アゴニストを含有してなる下部尿路系疾患の予防および/または治療剤 | |
JPWO2004014428A1 (ja) | 腸疾患および内臓痛の治療薬 | |
JP7338711B2 (ja) | Dpアンタゴニスト | |
WO2006115135A1 (ja) | 過敏性腸症候群治療剤 | |
JPWO2005079845A1 (ja) | 片頭痛予防薬 | |
WO2017119456A1 (ja) | せん妄の予防または治療剤 | |
JPWO2006085510A1 (ja) | 過敏性腸症候群の治療薬 | |
US20100137399A1 (en) | Preventive and/or therapeutic agent for urine collection disorder accompanying lower urinary tract obstruction | |
EP2172201A1 (en) | Pharmaceutical composition for amelioration of lower urinary tract symptom associated with prostatomegaly | |
WO2000075127A1 (fr) | Composes heterocycliques condenses a trois cycles, procede de preparation correspondant et utilisation de tels composes | |
EP4306115A1 (en) | Pharmaceutical composition, and preparation method therefor and application thereof | |
US20040248914A1 (en) | Method for the treatment of overactive bladder | |
JP2005060311A (ja) | N−(ベンゾイル)アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤 | |
WO2006077846A1 (ja) | 注意欠陥/多動性障害治療薬 | |
JP2005068141A (ja) | Vegf分泌亢進剤 | |
AU2002347708A1 (en) | Method for the treatment of overactive bladder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006510642 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2557758 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007167511 Country of ref document: US Ref document number: 10598533 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580007136.4 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5196/DELNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005719421 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067019606 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005719421 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067019606 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 10598533 Country of ref document: US |